An international group of diabetes researchers and clinicians have established a global database of new cases of diabetes in patients with Covid-19 – called the CoviDiab Registry Project. It comes off the back of initial observations that Covid-19 could potentially trigger diabetes and the urgent need to know more.
The goal of the registry is to collect data on people newly-diagnosed with diabetes and with confirmed Covid-19. It will also collect data on people with existing diabetes who present with Covid-19 and severe metabolic dysregulation, with the aim of investigating the pathogenesis of the interaction between the two conditions. Ultimately, researchers hope to understand whether Covid-19 causes a new form of diabetes or more simply a stress response that triggers classic type 1 or type 2 diabetes.
The CoviDiab team are calling for healthcare professionals to contribute patient data to the registry.
The registry will be fully anonymised and researchers will have no access to patients’ personal identifiers. Data about clinical observations will be entered by clinicians that are members of the care team for the individual patient or by authorised research personnel when data are transferred from other research databases.
To register as a contributor and enter data into the registry, sign up through CoviDiab.